CION Ameerpet
Immunotherapy · Melanoma & Skin Cancers
Acral and Mucosal Melanoma in India — Does Immunotherapy Work?
Most melanoma in India starts where nobody is looking for it: on the sole, on the palm, under a nail, or on an internal lining. Most people diagnosed with it are not candidates for immunotherapy at all — a melanoma removed completely by surgery is followed up, not treated with drugs. For the smaller group where the disease is advanced or at high risk of returning, immunotherapy is a recognised option. The honest answer is that these two subtypes respond less often than the sun-driven melanoma nearly every published figure describes.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Most patients are not candidates — melanoma that is completely removed by surgery is followed with examination and scans. Immunotherapy enters only for advanced disease, or for selected high-risk cases after surgery.
- Indian melanoma is a different disease — acral melanoma on the sole, palm or nail bed, and mucosal melanoma on internal linings, are not caused by ultraviolet light and carry far fewer mutations.
- Response is lower, not absent — NCCN and ESMO guidance, as of August 2026, reports lower response in these subtypes than in sun-driven melanoma. Responses still happen, and can last.
- Mutation testing changes the options — BRAF V600 is less common here, while KIT alterations are reported more often. Both findings open different conversations before anything is started.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
Who Is Eligible for Immunotherapy if the Melanoma Is Acral or Mucosal?
Most people diagnosed with acral or mucosal melanoma are not candidates for immunotherapy. A melanoma that has been completely removed by surgery is followed with examination and scans, and no drug treatment is given. Immunotherapy has a defined role in two situations only: disease that has spread and cannot be removed, and disease fully removed but carrying a high risk of returning.
Stage decides which conversation you are in. A thin melanoma confined to the skin of the sole or the nail bed is handled by surgery and follow-up. Melanoma that has reached lymph nodes, or travelled further, is where systemic treatment enters the discussion at all.
Your medical history matters next. Active autoimmune disease, an organ transplant, or ongoing high-dose steroids can make immunotherapy unsuitable or higher-risk. Checkpoint inhibitor treatment works by loosening restraints on the immune system rather than by attacking the tumour directly, so an immune system that is already over-active is a genuine problem, not a formality.
Then comes the part this page exists for. The subtype on the biopsy report is not a detail. Acral melanoma and mucosal melanoma behave differently from the sun-exposure-driven melanoma that almost all published data describes, and the difference is large enough to change what you should expect. Being told a melanoma response rate without being told which melanoma it refers to is close to being told nothing.
Nothing on this page decides eligibility. That rests on the biopsy report, the stage, previous treatment and overall fitness, read together by a medical oncologist.
The part nobody writes about
How Is Melanoma in India Different From Melanoma in the West?
Melanoma in India is mostly not the disease health campaigns describe. Instead of a changing mole on sun-exposed skin, it far more often starts on the sole of the foot, on the palm, or under a fingernail or toenail. That form is called acral melanoma, and it is reported as the most common subtype in Indian hospital series.
The second form is mucosal melanoma. It starts on an internal lining — the nasal cavity and sinuses, the mouth, the anorectal region, or the genital tract. It is uncommon everywhere, but it makes up a much larger share of melanoma in Indian and other Asian series than in Western ones.
Neither is caused by ultraviolet light. That single fact drives everything else on this page. Sun-driven melanoma accumulates thousands of small genetic errors from years of ultraviolet damage, and each error can produce an abnormal protein that immune cells recognise as foreign. Acral and mucosal melanoma do not have that history, so they carry a far lower mutation load and are correspondingly harder for the immune system to see.
The gene findings follow the same pattern. BRAF V600 mutations, which open the door to one class of targeted treatment, are much less common in acral and mucosal melanoma. Alterations in the KIT gene are reported more often. Large structural changes across whole stretches of chromosome are more typical than the point mutations of sun-driven disease.
Late diagnosis compounds it. A dark streak under a nail gets blamed on an injury or a fungal infection. A mark on the sole gets treated as a callus or a non-healing ulcer. Mucosal melanoma cannot be seen at all and announces itself with vague bleeding or blockage. By the time many Indian patients reach an oncologist, the tumour is thicker and the stage is higher than the trial populations behind the published figures.
Did you know?
A melanoma under a nail usually appears first as a dark brown or black streak running the length of the nail — not as a lump. It is routinely mistaken for a bruise from an old injury or for a fungal infection, and it is often treated as one for months. A single nail streak that is widening, that is darker at one edge, or where the pigment starts creeping onto the surrounding skin, deserves an examination rather than a wait-and-watch.
Three diseases, one name
Cutaneous, Acral and Mucosal Melanoma: What Actually Differs?
Read the table across, not down. The first column is what almost every melanoma article online is really about. The second and third are what most Indian patients actually have.
| What differs | Sun-driven cutaneous melanoma | Acral melanoma (sole, palm, nail bed) | Mucosal melanoma (nose, mouth, anorectal, genital) |
|---|---|---|---|
| Share of melanoma in India | A minority of cases | Reported as the most common subtype in Indian hospital series | Uncommon, but a far larger share than in Western series |
| What drives it | Ultraviolet damage accumulated over many years | Not caused by ultraviolet light; the cause is largely unknown | Not caused by ultraviolet light; the cause is largely unknown |
| Genetic mutation load | High — thousands of small errors from ultraviolet damage | Low, with more large structural changes across chromosomes | Low, with more large structural changes across chromosomes |
| BRAF V600 mutation | Common; opens a second class of targeted treatment | Much less common | Uncommon |
| KIT gene alteration | Rare | Reported more often than in sun-driven melanoma | Reported more often than in sun-driven melanoma |
| How it is usually found | A changing mole on sun-exposed skin, often at an early stage | Often late — mistaken for a bruise, callus, ulcer or fungal nail | Usually late — symptoms are vague, such as bleeding or blockage |
| Reported response to checkpoint inhibitor immunotherapy | The figures nearly all published data describes | Consistently reported as lower than cutaneous | Consistently reported as lower than cutaneous, and generally the lowest of the three |
| Strength of the evidence base | The largest, with the longest follow-up of any cancer treated this way | Smaller — subgroup analyses and registry series | Smallest — subgroup, pooled and registry analyses |
Guidance summarised from NCCN and ESMO melanoma recommendations current as of August 2026. No response percentage is quoted for acral or mucosal melanoma on this page, because a reliable single figure for these subtypes does not exist — and any page that gives you one should be read with caution.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Quoted a Melanoma Success Rate That May Not Apply to You?
Nearly every melanoma figure online describes sun-driven disease in fair-skinned populations. If the report says acral or mucosal, a medical oncologist will tell you plainly what does and does not carry across — free, and with no commitment to start treatment.
The honest answer
Does the Response to Immunotherapy Differ in Acral and Mucosal Melanoma?
Yes. Response is consistently reported as lower than in sun-driven melanoma. NCCN and ESMO guidance, current as of August 2026, addresses both subtypes and does not apply the cutaneous figures to them. Mucosal melanoma is generally reported as the least responsive of the three.
The reason is biological, not racial. Checkpoint inhibitor immunotherapy does not attack the tumour. It removes a brake on immune cells so that they can act on something they already recognise. If a tumour carries few abnormal proteins, there is less for those immune cells to recognise, and releasing the brake achieves less. Low mutation load is the single best explanation for the pattern seen in acral and mucosal disease.
Lower is not zero, and this is the part that gets lost. Responses do occur in both subtypes. When a response occurs it can be a lasting one, for the same reason it can be lasting in cutaneous melanoma: an immune response, once established, can persist after the drug stops. That is why immunotherapy remains a recognised option here rather than being written off.
What changes is the conversation you should be having. It is reasonable to ask your oncologist why immunotherapy is being proposed for your subtype, what the alternative sequence would be, what the plan is if the first assessment scan is disappointing, and whether a clinical trial is worth exploring. Trials in acral and mucosal melanoma exist and are informational to look into; no page can promise you a place in one.
At CION, immunotherapy itself is administered as day care at our centres. Assessment and follow-up CT and PET-CT imaging is coordinated at partner imaging centres.
Where the evidence comes from
What Is the Evidence for Immunotherapy in Acral and Mucosal Melanoma?
Weaker than for sun-driven melanoma, and it is better to know that than to be told otherwise. Both subtypes are uncommon, so only small numbers of these patients entered the trials that established checkpoint inhibitor immunotherapy. Almost none of those trials were designed to answer the question for them specifically.
What exists instead is three kinds of evidence. Subgroup analyses look at the handful of acral and mucosal patients inside larger cutaneous melanoma trials. Pooled analyses gather those small groups across several trials to reach numbers worth reporting. Registry and hospital series from Asian centres, where these subtypes are common, describe what happened to consecutive real patients rather than to a selected trial population.
Each of those has known weaknesses. Subgroups were never large enough to be conclusive on their own. Pooled analyses combine trials that differed in design. Registry series have no comparison group. Guideline bodies including NCCN and ESMO acknowledge all of this, address both subtypes explicitly, and grade the recommendation accordingly.
The practical consequence is that treatment decisions in acral and mucosal melanoma lean harder on individual judgement than they do in cutaneous melanoma. That is exactly the situation a tumour board is for. At CION every case is reviewed by medical, surgical and radiation oncologists together, so a decision made on incomplete evidence is at least made by more than one person.
Evidence in this area is genuinely immature. Anyone who tells you there is a settled answer for acral or mucosal melanoma is ahead of the published literature.
Before you agree to a plan
What Should You Check on the Report Before Starting Immunotherapy?
- Which subtype does the biopsy report name? Cutaneous, acral or mucosal. This one line decides which published evidence applies to you, and it changes it considerably.
- Has mutation testing been done, and what did it show? BRAF V600 and KIT status change which treatments exist for you and in what order they might be used. Ask for the result, not just for reassurance that it was sent.
- Is this treatment aimed at shrinking something, or at preventing a return? Advanced disease and post-surgery adjuvant treatment are different goals. Only the first has a response to measure on a scan at all.
- What is the plan if the first assessment scan is disappointing? Ask at the start rather than later. Knowing there is a defined next step makes the first decision easier to take, not harder.
- Which figures is the recommendation based on? A recommendation built on cutaneous melanoma data, applied to an acral or mucosal diagnosis, is worth naming out loud so that everyone is clear about what is known and what is assumed.
A second opinion is not disloyal
Have an Acral or Mucosal Melanoma Plan Reviewed
These subtypes are uncommon, the evidence behind them is thinner, and decisions lean harder on judgement. A tumour-board review costs you nothing and tells you whether the plan matches current NCCN and ESMO guidance for the subtype you actually have.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Acral and Mucosal Melanoma Immunotherapy — Your Questions Answered
How is melanoma in India different from melanoma in Western countries?
Most melanoma described in Western guidance starts on sun-exposed skin. In India a much larger share starts on the sole of the foot, the palm, or under a fingernail or toenail, which is called acral melanoma. Another share starts on an internal lining such as the nose, mouth, gut or genital tract, which is called mucosal melanoma. Neither is caused by ultraviolet light. Both carry far fewer genetic mutations than sun-driven melanoma. Both are also commonly found late, because the sites involved are easy to overlook. Different biology plus later diagnosis is why published melanoma figures often do not describe Indian patients well.
Does immunotherapy work for acral and mucosal melanoma?
It is used, and it is a recognised option in current NCCN and ESMO guidance for advanced disease. Response is consistently reported as lower than in sun-driven melanoma. The reason is biological rather than racial. Fewer mutations mean fewer abnormal proteins for immune cells to recognise as foreign. Lower is not zero. Responses do occur, and when they occur they can last a long time. What changes is the expectation you should set at the start. Ask your oncologist what the published evidence says for your specific subtype rather than for melanoma as a whole.
Am I eligible for immunotherapy if my melanoma was removed by surgery?
Usually not. Most melanoma that has been completely removed by surgery is followed with examination and scans, and no drug treatment is given. Immunotherapy has a defined role in two situations. The first is melanoma that has spread and cannot be removed by surgery. The second is melanoma that has been fully removed but carries a high risk of returning, where it may be offered after surgery to lower that risk. Active autoimmune disease, an organ transplant or ongoing high-dose steroids can also make it unsuitable. Eligibility is decided on the biopsy report, the stage and your overall fitness.
What evidence exists for immunotherapy in acral and mucosal melanoma?
Less than for sun-driven melanoma, and that is worth saying plainly. Both subtypes are uncommon, so only small numbers of these patients were included in the trials that established checkpoint inhibitor immunotherapy. Most of what is known comes from subgroup analyses within those trials, pooled analyses across several trials, and registry series from Asian centres where these subtypes are common. Guideline bodies including NCCN and ESMO address both subtypes and note the weaker evidence base. That is a reason for a careful individual discussion. It is not a reason to assume nothing works.
Should acral or mucosal melanoma be tested for gene mutations before treatment?
Testing is usually recommended, and it changes the conversation. BRAF V600 mutations, which open the door to one class of targeted treatment, are much less common in acral and mucosal melanoma than in sun-driven melanoma. Alterations in the KIT gene are reported more often in these two subtypes, and a KIT-directed targeted option may then be discussed. Knowing the mutation status before anything starts tells your oncologist which treatments exist for you and in what order they might be used. Ask whether the testing has been done and what it showed.
Why is melanoma under a nail or on the sole so often found late?
Because it does not look like the melanoma people are taught to watch for. On the sole or the palm it can be mistaken for a bruise, a wart, a callus or a non-healing ulcer. Under a nail it often begins as a dark brown or black streak running the length of the nail, which is easily blamed on an injury or a fungal infection. Mucosal melanoma sits inside the nose, mouth, gut or genital tract, where it cannot be seen and causes vague symptoms such as bleeding or blockage. A pigmented mark that is new, widening or not healing should be examined.
This page is general patient-education information, not a substitute for the written guidance an oncology team gives based on a specific diagnosis, biopsy report and treatment plan.